Pronóstico del mercado de la epilepsia en Europa hasta 2030: análisis regional por tipo (epilepsia mioclónica progresiva, epilepsia refleja, epilepsia generalizada y otras), vía de administración (oral, parenteral y otras), tipo de tratamiento (medicamentos de primera generación, medicamentos de segunda generación y medicamentos de tercera generación), grupo de edad (adultos y niños) y canal de distribución (farmacias hospitalarias, farmacias minoristas y otras)
El aumento de las inversiones en el desarrollo de terapias para la epilepsia impulsa el mercado europeo de la epilepsia
El sector sanitario se está transformando con rápidos avances tecnológicos e innovación, mejorando los servicios sanitarios y la calidad de la atención. El mercado de la epilepsia se caracteriza por la presencia de varias empresas y organizaciones pequeñas y grandes que implementan diversas estrategias de crecimiento. La disponibilidad de financiación permite a las empresas y organizaciones impulsar los niveles de producción, expandirse a nuevos mercados, invertir en tecnologías nuevas o mejoradas y asignar más recursos a I+D. A continuación se mencionan algunas de las inversiones notables en el mercado de la epilepsia, que contribuyen al progreso del mercado.
• En marzo de 2023, el gobierno sueco decidió encargar a Vinnova, la agencia de innovación de Suecia, un total de 7,7 millones de dólares (80 millones de coronas suecas) para establecer un clúster nacional de innovación para la comercialización, el desarrollo de habilidades y la creación de capacidad de producción para terapias celulares y otros tratamientos avanzados como la terapia génica.
• En noviembre de 2022, los científicos de la Universidad de Aston en el Reino Unido, que trabajan en un proyecto para desarrollar nuevos tratamientos farmacológicos para prevenir la aparición de la epilepsia infantil, recibieron 2,4 millones de dólares (2 millones de libras esterlinas) para descubrir el mecanismo de la enfermedad en el cerebro y las formas de prevención de la epilepsia. Este proyecto de tres años financiado por el Consejo de Investigación Médica es una colaboración dirigida por investigadores de la Facultad de Salud y Ciencias de la Vida de la Universidad de Aston, junto con la Universidad de Bristol y Jazz Pharmaceuticals.
• En julio de 2022, Cerebral Therapeutics obtuvo 40 millones de dólares en la ronda de financiación de la Serie C para preparar su tratamiento de infusión implantable para la epilepsia para el desarrollo de la fase 3. La ronda de financiación estuvo liderada por Lynx1 Capital Management, entre otros inversores, incluidos RA Capital Management y Perceptive Advisors. Cerebral Therapeutics pretende administrar los niveles especificados de valproato al sistema nervioso central sin provocar un aumento de peso, como se observó en sujetos de estudios de formulación oral.
• En noviembre de 2021, Neurava, una startup ubicada en Indiana, recibió más de US$ 0,65 millones en financiación inicial liderada por Elevate Ventures con la participación de Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures e inversores ángeles. La empresa está trabajando en el desarrollo de un dispositivo portátil para monitorear y alertar a los usuarios sobre el riesgo inminente de muerte súbita e inesperada causada por la epilepsia.
• En junio de 2021, Neurona Therapeutics Inc., una empresa de bioterapia, completó con éxito una financiación de 41,5 millones de dólares estadounidenses para avanzar en la línea de productos de terapias celulares listas para usar de propiedad absoluta de la empresa para diversas indicaciones, incluido NRTX-1001 (un estudio clínico de fase 1/2a), una terapia celular neuronal inhibidora para el tratamiento de la epilepsia focal crónica.
Por lo tanto, el aumento de las inversiones en el desarrollo de tratamientos avanzados impulsa el crecimiento del mercado de la epilepsia.
Descripción general del mercado de la epilepsia en Europa
El mercado europeo de la epilepsia está segmentado en Alemania, el Reino Unido, Francia, Italia, España y el resto de Europa. La región tiene una participación de mercado significativa en el mercado de la epilepsia. Se espera que el mercado europeo de la epilepsia experimente un crecimiento significativo durante el período de pronóstico debido a factores como el crecimiento significativo de la población de edad avanzada, las aprobaciones de nuevos medicamentos por parte de las autoridades reguladoras, el aumento de la financiación de los gobiernos para mejorar y desarrollar medicamentos y tratamientos efectivos para las convulsiones en la región.
Ingresos y pronóstico del mercado de la epilepsia en Europa hasta 2030 (millones de USD)
Segmentación del mercado de la epilepsia en Europa
El mercado de la epilepsia en Europa se clasifica en tipo, vía de administración, tipo de tratamiento, grupo de edad, canal de distribución y país.
Según el tipo, el mercado de la epilepsia en Europa se clasifica en epilepsia mioclónica progresiva, epilepsia refleja, epilepsia generalizada y otras. El segmento de la epilepsia generalizada tuvo la mayor participación de mercado en 2022.
En términos de vía de administración, el mercado de la epilepsia en Europa se clasifica en oral, parenteral y otras. El segmento oral tuvo la mayor participación de mercado en 2022.
Por tipo de tratamiento, el mercado de la epilepsia en Europa se segmenta en medicamentos de primera generación, medicamentos de segunda generación y medicamentos de tercera generación. El segmento de medicamentos de tercera generación tuvo la mayor participación de mercado en 2022.
Según el grupo de edad, el mercado de la epilepsia en Europa se bifurca en adultos y niños. El segmento de adultos tuvo una mayor participación de mercado en 2022.
En términos de canal de distribución, el mercado de la epilepsia en Europa se clasifica en farmacias hospitalarias, farmacias minoristas y otras. El segmento de farmacias hospitalarias tuvo la mayor participación de mercado en 2022.
Por país, el mercado de la epilepsia en Europa está segmentado en Reino Unido, Alemania, Francia, Italia, España y el resto de Europa. El Reino Unido dominó la cuota de mercado de la epilepsia en Europa en 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc y H. Lundbeck AS son algunas de las empresas líderes que operan en el mercado de la epilepsia en Europa.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Europe Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Europe Analysis
6.1 Europe: Epilepsy Market
7. Europe Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Europe Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Europe Epilepsy Market - Country Analysis
12.1 Europe: Epilepsy Market Overview
12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 United Kingdom: Epilepsy Market Overview
12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Germany: Epilepsy Market Overview
12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 France: Epilepsy Market Overview
12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Spain: Epilepsy Market Overview
12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 Italy: Epilepsy Market Overview
12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Europe: Epilepsy Market Overview
12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 CombiGene AB
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 LivaNova Plc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Medtronic Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 GSK Plc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 H. Lundbeck AS
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
?
List of Tables
Table 1. Europe Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. Europe Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
?
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- CombiGene AB
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.